Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. in September 2022. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.…
Lisata Therapeutics, Inc. Announces Reverse Stock Split Effective November 23, 2026
Lisata Therapeutics (NASDAQ: LSTA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 21 employees.
The shares were at 0.8989 USD on 20 November 2026, down 56.4% over 52 weeks. Its 52-week range is 0.8500 USD to 5.070 USD: the price is 82.3% below the high and 5.8% above the low.
Its market capitalisation is 9.71M USD.
Lisata Therapeutics reports return on equity of -111.7%.
It holds more cash than debt, a net cash position of 282.72M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.